SITE-DIRECTED DRUG DESIGN AGAINST PLASMODIUM FALCIPARUM

Information

  • Research Project
  • 3506031
  • ApplicationId
    3506031
  • Core Project Number
    R44AI025996
  • Full Project Number
    5R44AI025996-03
  • Serial Number
    25996
  • FOA Number
  • Sub Project Id
  • Project Start Date
    4/1/1988 - 36 years ago
  • Project End Date
    12/31/1991 - 33 years ago
  • Program Officer Name
  • Budget Start Date
    8/1/1990 - 34 years ago
  • Budget End Date
    12/31/1991 - 33 years ago
  • Fiscal Year
    1990
  • Support Year
    3
  • Suffix
  • Award Notice Date
    7/17/1990 - 34 years ago

SITE-DIRECTED DRUG DESIGN AGAINST PLASMODIUM FALCIPARUM

The ultimate objective of this project is to utilize the information available in the three-dimensional crystal structure of an enzyme in the rational design of drugs which will be effective against Plasmodium falciparum. The specific enzyme target is the bifunctional dihydrofolate reductase-thymidylate synthase (DHFR-TS) of P. falciparum. The achievement of this goal will involve a concerted effort along several fronts. First, the DHFR-TS gene must be isolated and cloned into an E. coli expression vector which will allow adequate overproduction of the protein. Second, chromatographic procedures will be devised for the isolation of homogeneous protein. Third, the protein will be crystallized and its three-dimensional structure discerned. Fourth, the three-dimensional space at the active site will be used for the design of chemical compounds which would be expected to bind tightly and be strongly inhibitory for the P. falciparum DHFT-TS while having much reduced affinity for the corresponding monofunctional human proteins. Fifth, the effectiveness of each compound will be examined by in vitro kinetic analysis. Successful compounds will offer an approach to controlling malaria, a disease with an incidence of approximately 200 million cases with greater than a million fatalities per year. Phase I will be concerned dominantly with the overproduction and purification of the enzyme and subsequent crystallization.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R44
  • Administering IC
    AI
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    SSS
  • Study Section Name
  • Organization Name
    AGOURON PHARMACEUTICALS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    SAN DIEGO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    921211122
  • Organization District
    UNITED STATES